PL1831252T3 - Preparaty białka fuzyjnego analogu GLP-1 - Google Patents

Preparaty białka fuzyjnego analogu GLP-1

Info

Publication number
PL1831252T3
PL1831252T3 PL05854150T PL05854150T PL1831252T3 PL 1831252 T3 PL1831252 T3 PL 1831252T3 PL 05854150 T PL05854150 T PL 05854150T PL 05854150 T PL05854150 T PL 05854150T PL 1831252 T3 PL1831252 T3 PL 1831252T3
Authority
PL
Poland
Prior art keywords
glp
fusion protein
fusion
formulations
protein formulations
Prior art date
Application number
PL05854150T
Other languages
English (en)
Inventor
Wolfgang Glaesner
Rohn Lee Junior Millican
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of PL1831252T3 publication Critical patent/PL1831252T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL05854150T 2004-12-22 2005-12-15 Preparaty białka fuzyjnego analogu GLP-1 PL1831252T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US64169004P 2004-12-22 2004-12-22
PCT/US2005/045376 WO2006068910A1 (en) 2004-12-22 2005-12-15 Glp-1 analog fusion protein formulations
EP05854150A EP1831252B1 (en) 2004-12-22 2005-12-15 Glp-1 analog fusion protein formulations

Publications (1)

Publication Number Publication Date
PL1831252T3 true PL1831252T3 (pl) 2009-11-30

Family

ID=36123207

Family Applications (1)

Application Number Title Priority Date Filing Date
PL05854150T PL1831252T3 (pl) 2004-12-22 2005-12-15 Preparaty białka fuzyjnego analogu GLP-1

Country Status (23)

Country Link
US (1) US20090232807A1 (pl)
EP (2) EP1831252B1 (pl)
JP (1) JP2008525452A (pl)
KR (1) KR100879662B1 (pl)
CN (1) CN101044162B (pl)
AT (1) ATE435235T1 (pl)
AU (1) AU2005319432A1 (pl)
BR (1) BRPI0519393A2 (pl)
CA (1) CA2589647A1 (pl)
CY (1) CY1109269T1 (pl)
DE (1) DE602005015257D1 (pl)
DK (1) DK1831252T3 (pl)
EA (1) EA011166B1 (pl)
ES (1) ES2326906T3 (pl)
HK (1) HK1107570A1 (pl)
IL (1) IL183285A0 (pl)
MX (1) MX2007007565A (pl)
NO (1) NO20073372L (pl)
PL (1) PL1831252T3 (pl)
PT (1) PT1831252E (pl)
SI (1) SI1831252T1 (pl)
UA (1) UA87009C2 (pl)
WO (1) WO2006068910A1 (pl)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100888022B1 (ko) * 2006-12-21 2009-03-09 재단법인 목암생명공학연구소 면역글로불린 Ｆｃ와 인간 아포리포단백질（ａ）크링글절편의 융합단백질 ＬＫ8­Ｆｃ
JP2008169195A (ja) 2007-01-05 2008-07-24 Hanmi Pharmaceutical Co Ltd キャリア物質を用いたインスリン分泌ペプチド薬物結合体
BRPI0813699B1 (pt) * 2007-07-10 2021-06-22 Eli Lilly And Company Formulação de proteína de fusão glp-1-fc
EP2031064A1 (de) * 2007-08-29 2009-03-04 Boehringer Ingelheim Pharma GmbH & Co. KG Verfahren zur Steigerung von Proteintitern
EP2435061A4 (en) 2009-05-28 2013-03-27 Amylin Pharmaceuticals Inc DAMPING GLP-1 RECEPTOR AGONIST COMPOUNDS
US20120294855A1 (en) 2009-11-03 2012-11-22 Eli Lilly & Company Glp-1 receptor agonist compounds for obstructive sleep apnea
US9487570B2 (en) * 2010-05-17 2016-11-08 Betta Pharmaceuticals Co., Ltd Glucagon like peptide analogs, composition, and method of use
CN102533655A (zh) * 2010-12-21 2012-07-04 青岛黄海制药有限责任公司 高效表达人源重组蛋白GLP1/Fc的CHO-S细胞株及其建立方法
EP2654767A4 (en) 2010-12-22 2014-05-21 Amylin Pharmaceuticals Inc GLP-1 RECEPTOR AGONISTS FOR ISLAND CELL TRANSPLANTATION
KR20130049671A (ko) 2011-11-04 2013-05-14 한미사이언스 주식회사 생리활성 폴리펩타이드 결합체 제조 방법
US10441665B2 (en) 2012-07-25 2019-10-15 Hanmi Pharm. Co., Ltd. Liquid formulation of long acting insulinotropic peptide conjugate
AR094821A1 (es) 2012-07-25 2015-09-02 Hanmi Pharm Ind Co Ltd Formulación líquida de un conjugado de péptido insulinotrópico de acción prolongada
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
CN104870009B (zh) 2012-12-21 2021-05-18 赛诺菲 官能化的毒蜥外泌肽-4衍生物
CN104173275A (zh) * 2013-05-21 2014-12-03 深圳翰宇药业股份有限公司 度拉鲁肽注射剂及其制备方法
CN104371019B (zh) 2013-08-13 2019-09-10 鸿运华宁（杭州）生物医药有限公司 一种能与glp-1r特异性结合的抗体及其与glp-1的融合蛋白质
EP3080149A1 (en) 2013-12-13 2016-10-19 Sanofi Dual glp-1/glucagon receptor agonists
EP3080152A1 (en) 2013-12-13 2016-10-19 Sanofi Non-acylated exendin-4 peptide analogues
EP3080154B1 (en) 2013-12-13 2018-02-07 Sanofi Dual glp-1/gip receptor agonists
TW201609795A (zh) 2013-12-13 2016-03-16 賽諾菲公司 作為雙重ｇｌｐ－１／ｇｉｐ受體促效劑的艾塞那肽－４（ｅｘｅｎｄｉｎ－４）胜肽類似物
KR102385120B1 (ko) * 2014-03-31 2022-04-12 한미약품 주식회사 면역글로불린 Fc 단편 결합을 이용한 단백질 및 펩타이드의 용해도를 개선시키는 방법
TW201625670A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
TW201625668A (zh) 2014-04-07 2016-07-16 賽諾菲公司 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
TW201625669A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
CN104327187B (zh) * 2014-10-11 2018-06-08 上海兴迪金生物技术有限公司 一种重组人GLP-1-Fc融合蛋白
WO2016077806A1 (en) * 2014-11-13 2016-05-19 AskGene Pharma, Inc. Fusion proteins with dual receptor agonist activities
KR102568272B1 (ko) 2015-02-11 2023-08-21 지맥스 바이오팜 엘엘씨 Ｇｌｐ-1ｒ 항체 융합 단백질의 안정한 약제학적 용액 제형
US10993993B2 (en) * 2015-05-28 2021-05-04 Immunoforge Co., Ltd. Pharmaceutical composition for treating muscle atrophy or sarcopenia including glucagon-like peptide (GLP-1) or GLP-1 receptor agonist
AR105319A1 (es) 2015-06-05 2017-09-27 Sanofi Sa Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
TW201706291A (zh) 2015-07-10 2017-02-16 賽諾菲公司 作為選擇性肽雙重ｇｌｐ－１／升糖素受體促效劑之新毒蜥外泌肽（ｅｘｅｎｄｉｎ－４）衍生物
NZ743474A (en) 2015-12-23 2023-03-31 Amgen Inc Method of treating or ameliorating metabolic disorders using binding proteins for gastric inhibitory peptide receptor (gipr) in combination with glp-1 agonists
GB201621987D0 (en) * 2016-12-22 2017-02-08 Archer Virgil L See Archer Sheri A Arecor Ltd Novel composition
JOP20190177A1 (ar) 2017-01-17 2019-07-16 Amgen Inc طريقة لعلاج أو تحسين اضطرابات أيضية باستخدام مساعدات مستقبل glp-1 مقترنة بمناهضات لمستقبل ببتيد مثبط معوي (gipr)
CR20190532A (es) 2017-06-20 2020-01-10 Amgen Inc Método para tratar o mejorar trastornos metabólicos con proteínas de unión para el receptor peptídico inhibidor gástrico (gipr) en combinación con agonistas de glp-1
KR20220146656A (ko) 2017-11-21 2022-11-01 일라이 릴리 앤드 캄파니 둘라글루티드를 함유하는 조성물 및 사용 방법
TWI829687B (zh) 2018-05-07 2024-01-21 丹麥商諾佛 儂迪克股份有限公司 包含glp-1促效劑與n-(8-(2-羥基苯甲醯基)胺基)辛酸之鹽的固體組成物
TWI705820B (zh) 2018-06-22 2020-10-01 美商美國禮來大藥廠 Gip/glp1促效劑組合物
US20220143187A1 (en) 2019-03-15 2022-05-12 Eli Lilly And Company Preserved formulations
CA3056663C (en) 2019-04-05 2022-10-18 Jeffrey S. RIESMEYER Use of dulaglutide in reducing risk of cardiovascular events in patients with type 2 diabetes mellitus
US20210187077A1 (en) * 2019-12-23 2021-06-24 Idaho State University GLP-1 Agonist Conjugates for Sustained Glycemic Control
WO2023125881A1 (zh) * 2021-12-31 2023-07-06 广东东阳光药业有限公司 Glp-1和gdf15的融合蛋白及其用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5118666A (en) * 1986-05-05 1992-06-02 The General Hospital Corporation Insulinotropic hormone
CN1117155C (zh) * 1994-07-29 2003-08-06 史密丝克莱恩比彻姆有限公司 新型化合物
GB9511935D0 (en) * 1995-06-13 1995-08-09 Smithkline Beecham Plc Novel compound
US6376653B1 (en) * 1998-09-28 2002-04-23 Smithkline Beecham Plc Tie2 antagonist antibodies
ES2311560T3 (es) * 2000-12-07 2009-02-16 Eli Lilly And Company Proteinas de fusion glp-1.
WO2002079415A2 (en) * 2001-03-30 2002-10-10 Lexigen Pharmaceuticals Corp. Reducing the immunogenicity of fusion proteins
US20030191056A1 (en) * 2002-04-04 2003-10-09 Kenneth Walker Use of transthyretin peptide/protein fusions to increase the serum half-life of pharmacologically active peptides/proteins
AU2004251145C1 (en) * 2003-06-12 2011-04-14 Eli Lilly And Company GLP-1 analog fusion proteins

Also Published As

Publication number Publication date
EA200701364A1 (ru) 2007-10-26
NO20073372L (no) 2007-07-16
KR100879662B1 (ko) 2009-01-20
DK1831252T3 (da) 2009-10-05
KR20070089187A (ko) 2007-08-30
PT1831252E (pt) 2009-09-17
IL183285A0 (en) 2007-09-20
ES2326906T3 (es) 2009-10-21
EP1831252B1 (en) 2009-07-01
EA011166B1 (ru) 2009-02-27
ATE435235T1 (de) 2009-07-15
CY1109269T1 (el) 2014-07-02
DE602005015257D1 (pl) 2009-08-13
SI1831252T1 (sl) 2009-12-31
US20090232807A1 (en) 2009-09-17
HK1107570A1 (en) 2008-04-11
UA87009C2 (ru) 2009-06-10
JP2008525452A (ja) 2008-07-17
AU2005319432A1 (en) 2006-06-29
EP1831252A1 (en) 2007-09-12
EP2168982A1 (en) 2010-03-31
CN101044162B (zh) 2010-10-27
WO2006068910A1 (en) 2006-06-29
MX2007007565A (es) 2007-07-24
CA2589647A1 (en) 2006-06-29
BRPI0519393A2 (pt) 2009-01-20
CN101044162A (zh) 2007-09-26

Similar Documents

Publication Publication Date Title
IL183285A0 (en) Glp-1 analog fusion protein formulations
TW200507870A (en) GLP-1 analog fusion proteins
WO2004093823A3 (en) Polyethelene glycol link glp-1 compounds
NO20076415L (no) GLP-1 pegylerte forbindelser
NZ515902A (en) Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, and type 2 diabetes
WO2007044591A3 (en) Vasoactive intestinal polypeptide pharmaceuticals
WO2005113606A3 (en) Fgf-21 fusion proteins
WO2006042152A3 (en) Vasoactive intestinal polypeptide pharmaceuticals
RS20060320A (en) Substituted indazole-o-glucosides
SG130189A1 (en) Substituted indole-o-glucosides
WO2005012318A3 (en) Substituted fused heterocyclic c-glycosides
UA86042C2 (en) Substituted indazole-o-glucosides
WO2007056362A3 (en) Glucagon analogs exhibiting physiological solubility and stability
WO2005089483A3 (en) Low glycemic sweeteners and products made using the same
MX2007007174A (es) Derivados de cicloalquilamina.
WO2003064619A3 (en) Long-acting hormone and growth factor compositions and uses thereof
WO2008155900A1 (ja) 糖鎖付加glp-1ペプチド
WO2002044113A3 (en) Use of(-) (3-halomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes, hyperlipidemia and hyperuricemia
MY134167A (en) Biphenylcarboxamides useful as lipid lowering agents
AU2002354269A1 (en) Pharmaceutical and foodstuff products comprising deuterium for the treatment of diabetes and methods for production thereof
WO2004069194A3 (en) Use of the oxidoreductase ncb50r for diagnosings and treating diabetes
WO2001087468A8 (en) Microfiltration using activated carbon
WO2003024946A3 (en) Oxamate derivatives containing a variously substituted nitrogen heterocycle
RS20060323A (en) Substituted indole-o-glucosides